Thiopurine S-methyltransferase as a target for drug interactions
- PMID: 15952020
- DOI: 10.1007/s00228-005-0950-5
Thiopurine S-methyltransferase as a target for drug interactions
Abstract
Objective: The present study was undertaken to investigate the possible effects of various agents on thiopurine methyltransferase (TPMT) activity in red blood cells (RBCs) from patients with chronic inflammatory bowel disease (IBD).
Methods: In three groups of patients with very high, normal and intermediate TPMT activity (each n=6), the inhibitory potential of furosemide, piretanide, azathioprine (AZA) and testosterone was assessed by ex vivo measurements of TPMT activity in RBCs. From individual concentration-response curves, IC50 values have been determined.
Results: Independent of the basal TPMT activity, lowest IC50 values were calculated for furosemide (15-19 microM), followed by testosterone (30-72 microM), piretanide (300-313 microM) and AZA (430-532 microM). Compared with reported plasma concentration achieved during treatment, only furosemide would have the potential to inhibit TPMT also in vivo, whereas the IC50 values of the other agents are far above the corresponding plasma levels.
Conclusions: Our ex vivo study revealed that only furosemide has the potential to inhibit TPMT activity in patients with IBD. This possibility should be taken into consideration if the diuretic and AZA or 6-mercaptopurine are coadministered. However, the extrapolation to the clinical setting remains open.
Similar articles
-
Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.Clin Gastroenterol Hepatol. 2008 Jun;6(6):654-60; quiz 604. doi: 10.1016/j.cgh.2008.02.032. Epub 2008 May 7. Clin Gastroenterol Hepatol. 2008. PMID: 18467186 Clinical Trial.
-
Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.Hepatogastroenterology. 2006 May-Jun;53(69):399-404. Hepatogastroenterology. 2006. PMID: 16795981 Clinical Trial.
-
Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide.Eur J Clin Pharmacol. 1996;49(5):393-6. doi: 10.1007/s002280050038. Eur J Clin Pharmacol. 1996. PMID: 8866635
-
Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions.Ther Drug Monit. 1998 Oct;20(5):527-31. doi: 10.1097/00007691-199810000-00014. Ther Drug Monit. 1998. PMID: 9780130 Review.
-
Thiopurines in Crohn's disease, is there something new?Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1505-14. doi: 10.1517/17425255.2010.525505. Epub 2010 Oct 5. Expert Opin Drug Metab Toxicol. 2010. PMID: 20919963 Review.
Cited by
-
Individualizing immunosuppression in lung transplantation.Glob Cardiol Sci Pract. 2018 Mar 14;2018(1):5. doi: 10.21542/gcsp.2018.5. Glob Cardiol Sci Pract. 2018. PMID: 29644232 Free PMC article. Review.
-
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.Clin Pharmacokinet. 2007;46(3):187-208. doi: 10.2165/00003088-200746030-00001. Clin Pharmacokinet. 2007. PMID: 17328579 Review.
-
Clinical pharmacology and pharmacogenetics of thiopurines.Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. doi: 10.1007/s00228-008-0478-6. Epub 2008 May 28. Eur J Clin Pharmacol. 2008. PMID: 18506437 Review.
-
In Vitro Protein Stability of Two Naturally Occurring Thiopurine S-Methyltransferase Variants: Biophysical Characterization of TPMT*6 and TPMT*8.ACS Omega. 2017 Aug 31;2(8):4991-4999. doi: 10.1021/acsomega.7b00801. Epub 2017 Aug 28. ACS Omega. 2017. PMID: 30023734 Free PMC article.
-
Advances in Thiopurine Drug Delivery: The Current State-of-the-Art.Eur J Drug Metab Pharmacokinet. 2021 Nov;46(6):743-758. doi: 10.1007/s13318-021-00716-x. Epub 2021 Sep 6. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34487330 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources